5MPA.SG - Midatech Pharma Plc

Stuttgart - Stuttgart Delayed price. Currency in EUR
-0.005 (-0.96%)
As of 8:04AM CEST. Market open.
Stock chart is not supported by your current browser
Previous close0.520
Bid0.000 x 100000
Ask0.000 x 100000
Day's range0.515 - 0.515
52-week range0.112 - 1.751
Avg. volume21
Market cap19.441M
PE ratio (TTM)N/A
EPS (TTM)-0.828
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswirelast month

    Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant

    Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focussed on developing and commercialising products in oncology and immunotherapy, today announces that, further to the Group’s announcement dated 20 December 2017, patient enrolment is now underway in its Gelclair® Phase IV trial in the US. The Phase IV trial, which is being conducted at both Dana-Farber/Brigham and Women’s Cancer Centre and Massachusetts General Hospital by the Group’s US subsidiary, Midatech Pharma US, has enrolled its first patient.  The trial has been designed to study the effects of Gelclair® (bioadherent oral gel) on various aspects of oral mucositis (“OM”) in patients undergoing stem cell transplant therapy (“SCT”).

  • We're sorry, but this is all we were able to find on this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes